Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory
Karyopharm Therapeutics Empresa reivindicada
Karyopharm is an innovation-driven pharmaceutical company whose core technology leverages the inhibition of nuclear export as a mechanism to treat patients with cancer and other medical conditions consulte Mais informação
There is a lack of transparency in GMSA and it creates a competitive environment. While I have full trust in the executive team, I do not trust my GMSA leadership team. I recommend this survey is sent to all employees as many others may agree. I recommend investing in a program to retain talent
Quais são algumas das melhores coisas da sua equipe?
Almost everyone on my team has strong work ethic and is collaborative.
O que faz você mais feliz no trabalho?
The potential to make an impact in patients and on the business
Qual é a coisa mais positiva da cultura e do ambiente da sua empresa?
High performers are rewarded as they should be. People are recognized for their hard work and effort. Nothing gets done with an n of one. We are all achieving greatness together.
Qual é a melhor parte das suas compensações?
I am compensated well however I am working harder than I ever have and I don’t feel that I am compensated at that level. I have done this same role at prior companies and been compensated the same
O que você mais gosta nos lideres?
The executive team has a perfect balance of being committed to furthering the science and helping patients while understanding what it means to run a business. What Karyopharm has accomplished in the past decade is truly impressive and that speaks to diligence and commitment of this leadership team.
Other Employee Reviews for Karyopharm Therapeutics
×